## Note
nid: 1495818787111
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::22_Imatinib_Dasatinib_Nilotinib, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Pixorize::01_Immunology::07_Leukemias_&_Lymphomas::03_CML, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::18_Imatinib,_Dasatinib, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Imatinib,_Dasatinib, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::01_Imatinib,_erlotinib,_sorafenib,_sunitinib,_vemurafenib::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield
markdown: false

### Text
<div>
  <div>
    <b>Imatinib</b> is a(n) {{c1::competitive}} inhibitor of the
    <i><b>Bcr-Abl</b> fusion protein</i>
  </div>
</div>

### Extra
<img src="432px-Mechanism_imatinib.svg.png">
<div>
  <i><b>FA 2019</b>: now also lists <b>dasatinib</b></i>
</div>
<div><img src="paste-735654883360769.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-37280316129283%20(1).jpg"><img src=
"paste-323204878958595.jpg"><img src=
"paste-326542068547587.jpg"><img src="paste-330222855520259.jpg">
<!--EndFragment-->

### Sketchy
<img src="paste-386186279387137.jpg" class="resizer"><img src=
"paste-6ef6236c9786ccaaf69cacfab716239d037e3c2e.png" class=
"resizer"> <a href=
"https://dashboard.sketchy.com/study/medical/courses/medical-pharmacology/units/medical-pharmacology-antineoplastics/videos/medical-pharmacology-antineoplastics-kinase-inhibitors-and-monoclonal-antibodies-imatinib-erlotinib-sorafenib-sunitinib-vemurafenib?utm_source=anki&utm_medium=partnership&utm_campaign=february_update&utm_content=medical">
Watch Imatinib, erlotinib, sorafenib, sunitinib, vemurafenib</a>

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_7.png"></a>
</div>

### Additional Resources


### One by one

